[시장보고서]T 세포 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료법 유형별, 적응증별(혈액 악성 종양, 고형 종양, 기타), 지역별, 경쟁별(2020-2030년)

T 세포 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료법 유형별, 적응증별(혈액 악성 종양, 고형 종양, 기타), 지역별, 경쟁별(2020-2030년)

T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Indication (Hematologic Malignancies, Solid Tumors, Others), By Region and Competition, 2020-2030F

상품코드 : 1881827

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 183 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,699,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,188,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,910,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 T 세포 치료 시장은 2024년에 29억 2,000만 달러로 평가되었으며, 2030년까지 CAGR 9.9%로 성장하여 51억 4,000만 달러에 달할 것으로 예측됩니다.

T 세포 치료는 면역치료의 일종으로 환자 자신의 T 세포를 변형시켜 주로 암세포 등 병변세포를 식별하고 제거하는 능력을 향상시키는 치료법입니다. 시장 확대는 전 세계적으로 증가하는 각종 암 발병률, 유전공학 기술의 지속적인 발전, 새로운 면역치료법 연구개발에 대한 막대한 투자에 의해 크게 촉진되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	29억 2,000만 달러
시장 규모 : 2030년	51억 4,000만 달러
CAGR : 2025-2030년	9.9%
가장 빠르게 성장하는 부문	T 세포 수용체(TCR) 기반
최대 시장	북미

주요 시장 촉진요인

전 세계적으로 증가하는 암 부담은 T 세포 치료를 포함한 혁신적인 치료 솔루션에 대한 지속적이고 큰 수요 요인으로 작용하고 있습니다. 전 세계적으로 다양한 암의 종류가 증가함에 따라, 특히 기존 치료법에 내성이 있는 환자들에게 치료 효과와 환자 예후를 개선하는 첨단 치료법의 지속적인 개발 및 도입이 요구되고 있습니다.

주요 시장 과제

복잡하고 자원 집약적인 제조 공정으로 인해 맞춤형 T 세포 치료제의 본질적인 고비용은 시장 확대에 큰 장벽으로 작용하고 있습니다. 이러한 치료법은 환자 자신의 T 세포를 개별적으로 변형시켜야 하기 때문에 제조 비용이 높습니다.

주요 시장 동향

동종 T 세포 치료로의 전환은 환자의 자가 세포에 의존하는 개별화된 자가 치료에서 벗어나 세계 T 세포 치료 시장에서 중요한 진화 단계입니다. 이러한 전환은 맞춤형 치료의 고유한 제조상의 복잡성과 높은 비용을 해결하기 위한 것으로, 보다 쉽게 접근할 수 있는 '기성품' 제품의 길을 열어주는 것입니다.

영문목차

The Global T-cell Therapy Market, valued at USD 2.92 Billion in 2024, is projected to experience a CAGR of 9.9% to reach USD 5.14 Billion by 2030. T-cell therapy represents a specialized form of immunotherapy that involves modifying a patient's own T-cells to enhance their ability to identify and eliminate diseased cells, primarily cancerous ones. The market's expansion is significantly propelled by the increasing global prevalence of various cancers, continuous technological advancements in genetic engineering techniques, and substantial investments directed towards research and development for novel immunotherapeutic approaches.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.92 Billion
Market Size 2030	USD 5.14 Billion
CAGR 2025-2030	9.9%
Fastest Growing Segment	T Cell Receptor (TCR)-based
Largest Market	North America

Key Market Drivers

The escalating global burden of cancer presents a substantial and persistent demand driver for innovative therapeutic solutions, including T-cell therapy. The increasing incidence of various cancer types globally necessitates the continuous development and adoption of advanced treatment modalities that offer improved efficacy and patient outcomes, particularly for those refractory to conventional therapies. This pressing medical need directly fuels investment and research into T-cell therapies, positioning them as critical options in oncology. According to the American Cancer Society and the International Agency for Research on Cancer, April 2024, Global Cancer Statistics 2024, close to 20 million cancer cases were newly diagnosed in 2022 around the world, underscoring the vast and growing patient population requiring novel interventions.

Key Market Challenges

The inherently high cost associated with personalized T-cell therapies, driven by complex and resource-intensive manufacturing processes, presents a significant impediment to market expansion. These treatments necessitate individual modification of a patient's own T-cells, leading to high production expenses. This directly restricts widespread patient access and imposes considerable financial pressure on healthcare systems and payers globally. Consequently, the adoption rate of these innovative therapies is constrained, preventing broader market penetration despite their demonstrated clinical efficacy.

Key Market Trends

The shift towards allogeneic T-cell therapies represents a significant evolutionary step in the global T-cell therapy market, moving away from individualized autologous treatments which rely on a patient's own cells. This transition aims to address the inherent manufacturing complexities and high costs associated with personalized therapies, paving the way for more readily available, "off-the-shelf" products. These allogeneic platforms, utilizing donor cells, hold the potential to enhance scalability and accessibility, thereby broadening the eligible patient population. According to the Alliance for Regenerative Medicine, in January 2024, the sector anticipated the potential for the first United States approval of an allogeneic T-cell therapy that year.

Key Market Players

Novartis AG
Merck KGaA
Gilead Sciences Inc.
TCR2 Therapeutics Inc
Bluebird Bio Inc.
Sorrento Therapeutics Inc.
Fate Therapeutics Inc.
Pfizer Inc.
Amgen Inc
Celgene Corporation

Report Scope:

In this report, the Global T-cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

T-cell Therapy Market, By Therapy Type:

CAR T-cell Therapy
T Cell Receptor (TCR)-based
Tumor Infiltrating Lymphocytes (TIL)-based)

T-cell Therapy Market, By Indication:

Hematologic Malignancies
Solid Tumors
Others

T-cell Therapy Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global T-cell Therapy Market.

Available Customizations:

Global T-cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global T-cell Therapy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based))
- 5.2.2. By Indication (Hematologic Malignancies, Solid Tumors, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America T-cell Therapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapy Type
- 6.2.2. By Indication
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States T-cell Therapy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapy Type
    - 6.3.1.2.2. By Indication
- 6.3.2. Canada T-cell Therapy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapy Type
    - 6.3.2.2.2. By Indication
- 6.3.3. Mexico T-cell Therapy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapy Type
    - 6.3.3.2.2. By Indication

7. Europe T-cell Therapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Therapy Type
- 7.2.2. By Indication
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany T-cell Therapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapy Type
    - 7.3.1.2.2. By Indication
- 7.3.2. France T-cell Therapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapy Type
    - 7.3.2.2.2. By Indication
- 7.3.3. United Kingdom T-cell Therapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapy Type
    - 7.3.3.2.2. By Indication
- 7.3.4. Italy T-cell Therapy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapy Type
    - 7.3.4.2.2. By Indication
- 7.3.5. Spain T-cell Therapy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapy Type
    - 7.3.5.2.2. By Indication

8. Asia Pacific T-cell Therapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Therapy Type
- 8.2.2. By Indication
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China T-cell Therapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapy Type
    - 8.3.1.2.2. By Indication
- 8.3.2. India T-cell Therapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapy Type
    - 8.3.2.2.2. By Indication
- 8.3.3. Japan T-cell Therapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapy Type
    - 8.3.3.2.2. By Indication
- 8.3.4. South Korea T-cell Therapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapy Type
    - 8.3.4.2.2. By Indication
- 8.3.5. Australia T-cell Therapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapy Type
    - 8.3.5.2.2. By Indication

9. Middle East & Africa T-cell Therapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapy Type
- 9.2.2. By Indication
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia T-cell Therapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapy Type
    - 9.3.1.2.2. By Indication
- 9.3.2. UAE T-cell Therapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapy Type
    - 9.3.2.2.2. By Indication
- 9.3.3. South Africa T-cell Therapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapy Type
    - 9.3.3.2.2. By Indication

10. South America T-cell Therapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapy Type
- 10.2.2. By Indication
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil T-cell Therapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapy Type
    - 10.3.1.2.2. By Indication
- 10.3.2. Colombia T-cell Therapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapy Type
    - 10.3.2.2.2. By Indication
- 10.3.3. Argentina T-cell Therapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapy Type
    - 10.3.3.2.2. By Indication

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global T-cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Merck KGaA
15.3. Gilead Sciences Inc.
15.4. TCR2 Therapeutics Inc
15.5. Bluebird Bio Inc.
15.6. Sorrento Therapeutics Inc.
15.7. Fate Therapeutics Inc.
15.8. Pfizer Inc.
15.9. Amgen Inc
15.10. Celgene Corporation

한글목차

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 T 세포 치료 시장 전망

제6장 북미의 T 세포 치료 시장 전망

제7장 유럽의 T 세포 치료 시장 전망

제8장 아시아태평양의 T 세포 치료 시장 전망

제9장 중동 및 아프리카의 T 세포 치료 시장 전망

제10장 남미의 T 세포 치료 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 T 세포 치료 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항